Skip to main content
. Author manuscript; available in PMC: 2018 Oct 25.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Apr 4;22(7):1218–1226. doi: 10.1016/j.bbmt.2016.03.027

Figure 3:

Figure 3:

Cumulative incidence of relapse with non-relapse mortality as the competing event (A) and non-relapse mortality with relapse as the competing event (B) by the type of post-remission therapy in first complete remission. The 3-year cumulative incidence of relapse was 68% and 41% with chemotherapy and HSCT respectively. The 3-year cumulative incidence of non-relapse mortality was 15% and 13% with chemotherapy and HSCT respectively.